Literature DB >> 15972495

Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.

Makda Fisseha1, Ping Chen, Brenda Brandt, Todd Kijek, Elizabeth Moran, Wendell Zollinger.   

Abstract

Native outer membrane vesicles (NOMV) of Neisseria meningitidis consist of intact outer membrane and contain outer membrane proteins (OMP) and lipooligosaccharides (LOS) in their natural conformation and membrane environment. NOMV have been safely used intranasally in P1 studies with encouraging results, but they are too toxic for parenteral vaccination. We now report the preparation and characterization of lpxL mutants that express LOS with reduced toxicity, and the evaluation of the potential of NOMV from these strains for use as a parenteral vaccine. A series of deletion mutants were prepared with knockouts of one or more of the lpxL1, lpxL2, or synX genes. The deltalpxL2 mutants had a reduced growth rate, reduced level of LOS expression, and increased sensitivity to surfactants. In addition, deltasynX deltalpxL2 double mutants had reduced viability in stationary phase. The deltalpxL1 deltalpxL2 double mutant behaved essentially the same as the deltalpxL2 single mutant. LOS from both lpxL mutant strains exhibited altered migration on polyacrylamide gels. The LOS of deltalpxL2 mutants of L3,7 strains were fully sialylated. NOMV prepared from lpxL2 mutants was about 200-fold less active than wild-type NOMV in rabbit pyrogen tests and in tumor necrosis factor alpha release assays. Bactericidal titers induced in animals by deltalpxL2 mutant NOMV were lower than those induced by deltalpxL1 or wild-type NOMV. However, immunogenicity could be largely restored by use of an adjuvant. These results provide evidence that NOMV from deltalpxL2 mutant strains will be safe and immunogenic in humans when given parenterally.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972495      PMCID: PMC1168616          DOI: 10.1128/IAI.73.7.4070-4080.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Authors:  Rohit K Katial; Brenda L Brandt; Ellen E Moran; Stephen Marks; Victor Agnello; Wendell D Zollinger
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Phosphorylation of the lipid A region of meningococcal lipopolysaccharide: identification of a family of transferases that add phosphoethanolamine to lipopolysaccharide.

Authors:  Andrew D Cox; J Claire Wright; Jianjun Li; Derek W Hood; E Richard Moxon; James C Richards
Journal:  J Bacteriol       Date:  2003-06       Impact factor: 3.490

3.  The lipopolysaccharide barrier: correlation of antibiotic susceptibility with antibiotic permeability and fluorescent probe binding kinetics.

Authors:  D S Snyder; T J McIntosh
Journal:  Biochemistry       Date:  2000-09-26       Impact factor: 3.162

4.  Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Authors:  B Haneberg; R Dalseg; E Wedege; E A Høiby; I L Haugen; F Oftung; S R Andersen; L M Naess; A Aase; T E Michaelsen; J Holst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

5.  Introduction of a conjugate meningococcal type C vaccine programme in the UK.

Authors:  D Salisbury
Journal:  J Paediatr Child Health       Date:  2001-10       Impact factor: 1.954

6.  Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity.

Authors:  P van der Ley; L Steeghs; H J Hamstra; J ten Hove; B Zomer; L van Alphen
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

7.  Extragenic suppressors of growth defects in msbB Salmonella.

Authors:  S R Murray; D Bermudes; K S de Felipe; K B Low
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

8.  The Neisseria gonorrhoeae lpxLII gene encodes for a late-functioning lauroyl acyl transferase, and a null mutation within the gene has a significant effect on the induction of acute inflammatory responses.

Authors:  C D Ellis; B Lindner; C M Anjam Khan; U Zähringer; R Demarco de Hormaeche
Journal:  Mol Microbiol       Date:  2001-10       Impact factor: 3.501

9.  A cell line assay system for predicting the response of human blood to endotoxin.

Authors:  Akihiko Yamamoto; Takeo Sakai; Masaki Ochiai; Kazunari Kamachi; Michiyo Kataoka; Hiromi Toyoizumi; Yoshinobu Horiuchi
Journal:  Jpn J Infect Dis       Date:  2003-06       Impact factor: 1.362

10.  The msbB mutant of Neisseria meningitidis strain NMB has a defect in lipooligosaccharide assembly and transport to the outer membrane.

Authors:  Deborah M B Post; Margaret R Ketterer; Nancy J Phillips; Bradford W Gibson; Michael A Apicella
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

View more
  31 in total

1.  Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Authors:  Wendell D Zollinger; Elizabeth E Moran; Deborah H Schmiel
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

2.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

3.  The transcriptional repressor FarR is not involved in meningococcal fatty acid resistance mediated by the FarAB efflux pump and dependent on lipopolysaccharide structure.

Authors:  Stephanie Schielke; Corinna Schmitt; Carolin Spatz; Matthias Frosch; Alexandra Schubert-Unkmeir; Oliver Kurzai
Journal:  Appl Environ Microbiol       Date:  2010-03-26       Impact factor: 4.792

4.  Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Authors:  Oliver Koeberling; Anja Seubert; George Santos; Annalisa Colaprico; Mildred Ugozzoli; John Donnelly; Dan M Granoff
Journal:  Vaccine       Date:  2011-05-13       Impact factor: 3.641

Review 5.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

6.  Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.

Authors:  Elizabeth E Moran; Robert Burden; Joseph E Labrie; Zhiyun Wen; Xin-Min Wang; Wendell D Zollinger; Lan Zhang; Valerian B Pinto
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

7.  Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice.

Authors:  Stefan Schild; Eric J Nelson; Andrew Camilli
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

8.  Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.

Authors:  V Weynants; P Denoël; N Devos; D Janssens; C Feron; K Goraj; P Momin; D Monnom; C Tans; A Vandercammen; F Wauters; Jan T Poolman
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

9.  Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants.

Authors:  Mark B Stoddard; Valerian Pinto; Paul B Keiser; Wendell Zollinger
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

10.  Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis.

Authors:  Liana Steeghs; A Marijke Keestra; Andries van Mourik; Heli Uronen-Hansson; Peter van der Ley; Robin Callard; Nigel Klein; Jos P M van Putten
Journal:  Infect Immun       Date:  2008-05-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.